Cangrelor — Discount Pricing

Other medications in Heart & Cardiovascular

• Captopril
• Carvedilol
• Chlorthalidone
• Cholestyramine
• Colesevelam
• Colestipol
• Colestipol (Lipid)
• Dapagliflozin (HF)

About Cangrelor

Cangrelor (brand name Kengreal) is a critical intravenous medication used during specific heart procedures to prevent dangerous blood clots. As a rapid-onset antiplatelet drug, it offers immediate protection when time is of the essence. For members of TheDrugClub, understanding your medication options and potential savings is key, and we're here to help you navigate the costs associated with vital treatments like cangrelor.

Cangrelor is an essential antiplatelet medication primarily utilized in a critical medical setting: during percutaneous coronary intervention (PCI). PCI, often referred to as angioplasty with stenting, is a procedure designed to open narrowed or blocked coronary arteries, restoring blood flow to the heart. Cangrelor is specifically indicated for patients undergoing PCI who have not been pre-treated with an oral P2Y12 inhibitor, or for whom an oral inhibitor is not feasible or effective. Its role is to rapidly prevent platelets from clumping together, thereby reducing the risk of serious cardiovascular events such as heart attack, stroke, and stent thrombosis during and immediately after the procedure.

How Cangrelor Works Its Magic

Cangrelor operates as a direct-acting P2Y12 platelet inhibitor. In simpler terms, it quickly blocks a specific receptor on the surface of platelets, preventing them from activating and forming clots. What makes cangrelor unique is its rapid onset of action and very short half-life, meaning its effects appear quickly and wear off just as fast once the infusion is stopped. This precise control is crucial in a procedural setting, allowing clinicians to manage bleeding risks effectively while providing robust antiplatelet protection when it's most needed. Admin

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Cangrelor is approved for (FDA label)

KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y 12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor [see Clinical Studies ( 14.1 )]. KENGREAL is a P2Y 12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y 12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: October 21, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Cangrelor (FDA label)

For Injection: 50 mg of KENGREAL lyophilized powder in a single-use 10 mL glass vial for reconstitution. Single-use 10 mL vial containing 50 mg KENGREAL as a lyophilized powder for reconstitution ( 3.0 )

Source: FDA prescribing information (DailyMed). Set ID: 88b434fa-8891-4fd5-9d86-7ea64667c08f. SPL document ID: 8c5e6180-c346-48e7-818d-471089de4ee7. Label effective date: October 21, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Cangrelor (FDA label)

The following adverse reactions are also discussed elsewhere in the labeling: Bleeding [see Warnings and Precautions ( 5.1 )] The most common adverse reaction is bleeding. ( 5.1 , 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA, Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of KENGREAL has been evaluated in 13,301 subjects in controlled trials, in whom, 5,529 were in the CHAMPION PHOENIX trial.

Source: FDA prescribing information (DailyMed). Set ID: 88b434fa-8891-4fd5-9d86-7ea64667c08f. SPL document ID: 8c5e6180-c346-48e7-818d-471089de4ee7. Label effective date: October 21, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Cangrelor (FDA label)

Significant active bleeding ( 4.1 ) Hypersensitivity to KENGREAL or any component of the product ( 4.2 ) 4.1 Significant Active Bleeding KENGREAL is contraindicated in patients with significant active bleeding [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . 4.2 Hypersensitivity KENGREAL is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to KENGREAL or any component of the product [see Adverse Reactions ( 6.1 )] . 4.1 Significant Active Bleeding KENGREAL is contraindicated in patients with significant active bleeding [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . 4.2 Hypersensitivity KENGREAL is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to KENGREAL or any component of the product [see Adverse Reactions ( 6.1 )] .

Source: FDA prescribing information (DailyMed). Set ID: 88b434fa-8891-4fd5-9d86-7ea64667c08f. SPL document ID: 8c5e6180-c346-48e7-818d-471089de4ee7. Label effective date: October 21, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Cangrelor (FDA label)

Bleeding: Like other drugs that inhibit platelet P2Y 12 function, KENGREAL can increase the risk of bleeding ( 5.1 ) 5.1 Bleeding Drugs that inhibit platelet P2Y 12 function, including KENGREAL, increase the risk of bleeding. In CHAMPION PHOENIX bleeding events of all severities were more common with KENGREAL than with clopidogrel [see Adverse Reactions ( 6.1 )] . Bleeding complications with KENGREAL were consistent across a variety of clinically important subgroups (see Figure 1). Once KENGREAL is discontinued, there is no antiplatelet effect after an hour [see Clinical Pharmacology ( 12.3 )] . 5.1 Bleeding Drugs that inhibit platelet P2Y 12 function, including KENGREAL, increase the risk of bleeding. In CHAMPION PHOENIX bleeding events of all severities were more common with KENGREAL than with clopidogrel [see Adverse Reactions ( 6.1 )] . Bleeding complications with KENGREAL were consistent across a variety of clinically important subgroups (see Figure 1).

Source: FDA prescribing information (DailyMed). Set ID: 88b434fa-8891-4fd5-9d86-7ea64667c08f. SPL document ID: 8c5e6180-c346-48e7-818d-471089de4ee7. Label effective date: October 21, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Cangrelor (FDA label)

Clopidogrel: Do not administer during KENGREAL infusion. ( 7.1 ) Prasugrel: Do not administer during KENGREAL infusion. ( 7.1 ) 7.1 Thienopyridines Clopidogrel or prasugrel administered during KENGREAL infusion will have no antiplatelet effect until the next dose is administered. Therefore, administer clopidogrel or prasugrel after KENGREAL infusion is discontinued [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )]. 7.1 Thienopyridines Clopidogrel or prasugrel administered during KENGREAL infusion will have no antiplatelet effect until the next dose is administered. Therefore, administer clopidogrel or prasugrel after KENGREAL infusion is discontinued [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )].

Source: FDA prescribing information (DailyMed). Set ID: 88b434fa-8891-4fd5-9d86-7ea64667c08f. SPL document ID: 8c5e6180-c346-48e7-818d-471089de4ee7. Label effective date: October 21, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.